share_log

Ginkgo Bioworks | 10-Q: Quarterly report

Ginkgo Bioworks | 10-Q: Quarterly report

Ginkgo Bioworks | 10-Q:季度报表
美股sec公告 ·  05/09 16:22
Moomoo AI 已提取核心信息
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce...Show More
Ginkgo Bioworks Holdings, Inc. reported a decrease in total revenue for the first quarter ended March 31, 2024, with revenues falling to $37.944 million from $80.702 million in the same period last year. The company's Cell Engineering segment saw a decrease in revenue from $34.096 million to $27.889 million, while the Biosecurity segment's revenue dropped significantly from $46.606 million to $10.055 million. The total segment operating loss widened to $123.662 million from $116.410 million year-over-year. The diluted net loss per share remained constant at $0.08, improving from a net loss of $0.11 per share in the previous year. Ginkgo Bioworks also reported a net loss of $165.911 million, an improvement from a net loss of $204.969 million in the first quarter of 2023. The company has undertaken restructuring actions to reduce operational expenditures, including labor expense reductions and facility consolidations, expected to commence in the second quarter of 2024. Additionally, Ginkgo acquired platform assets from AgBiome, Inc. on April 10, 2024, to enhance its Ag Biologicals Services. Looking forward, Ginkgo Bioworks aims to leverage its Foundry and Codebase assets to drive scale and learning efficiencies across diverse markets, with a focus on improving the probability of successful product development for its customers.
Ginkgo Bioworks Holdings, Inc.报告称,截至2024年3月31日的第一季度总收入有所下降,收入从去年同期的8,070.2万美元降至3794.4万美元。该公司的细胞工程板块收入从3,409.6万美元下降至2789万美元,而生物安全板块的收入从4,6606万美元大幅下降至1,005.5万美元。该细分市场的总营业亏损从同比1.1641亿美元扩大至1.23662亿美元。摊薄后的每股净亏损保持不变,为0.08美元,高于去年的每股净亏损0.11美元。Ginkgo Bioworks还报告净亏损1.65911亿美元,较2023年第一季度的净亏损2.04969亿美元有所改善。该公司已...展开全部
Ginkgo Bioworks Holdings, Inc.报告称,截至2024年3月31日的第一季度总收入有所下降,收入从去年同期的8,070.2万美元降至3794.4万美元。该公司的细胞工程板块收入从3,409.6万美元下降至2789万美元,而生物安全板块的收入从4,6606万美元大幅下降至1,005.5万美元。该细分市场的总营业亏损从同比1.1641亿美元扩大至1.23662亿美元。摊薄后的每股净亏损保持不变,为0.08美元,高于去年的每股净亏损0.11美元。Ginkgo Bioworks还报告净亏损1.65911亿美元,较2023年第一季度的净亏损2.04969亿美元有所改善。该公司已采取重组行动以减少运营支出,包括削减劳动力开支和整合设施,预计将于2024年第二季度开始。此外,Ginkgo于2024年4月10日收购了AgBiome, Inc.的平台资产,以加强其农业生物制品服务。展望未来,Ginkgo Bioworks的目标是利用其Foundry和Codebase资产来提高不同市场的规模和学习效率,重点是提高其客户成功开发产品的可能性。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息